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Aims In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejec-
tion fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]. Efficacy of
these agents was also shown when they were administered to patients with left ventricular dysfunction and signs and
symptoms of CHF early after acute myocardial infarction. It is not known whether the selective aldosterone antag-
onist eplerenone can improve outcomes in mildly symptomatic patients. The Eplerenone in Mild Patients Hospital-
ization And SurvIval Study in Heart Failure (EMPHASIS-HF) was designed to evaluate the effect of eplerenone on
mortality and morbidity in patients with chronic systolic HF in NYHA class II.
Methods Approximately 3100 patients with ejection fraction ≤30% and estimated glomerular filtration rate ≥30 mL/min/
1.73 m2 will be recruited. Patients are randomized 1:1 to double-blind eplerenone or placebo in addition to standard
chronic HF therapy. Doses are adjusted from 25 mg every other day to 50 mg daily, depending on serum potassium.
The primary endpoint is a composite of time to cardiovascular death or first hospital admission for worsening HF,
whichever occurs first.
Conclusion The study will be complete when approximately 813 subjects experience a primary endpoint.
Clinical Trials.gov. NCT00232180.
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Introduction
Aldosterone plays an important role in the pathophysiology of
heart failure (HF),1,2 and mineralocorticoid receptors (MRs) are
over-expressed in the myocardium of the failing heart.3,4 Despite
chronic angiotensin-converting enzyme (ACE)-inhibitor (ACE-I)
therapy,5,6 b-blocker therapy,7 and angiotensin receptor blocker
(ARB) therapy,8 patients with even mild symptoms of HF have
elevated plasma aldosterone levels,9 although combined ACE and
ARB therapy was recently reported to give a sustained decrease
in aldosterone levels.10
In patients with a low left ventricular ejection fraction (LVEF)
and severe symptoms [New York Heart Association (NYHA)
class III or IV], adding the aldosterone (receptor) blocker (AB) spir-
onolactone 25 mg daily to standard therapy (ACE-I and loop diure-
tic) resulted in a 30% reduction in the relative risk of all-cause
mortality in the placebo-controlled Randomized Aldactone
Evaluation Study (RALES). Spironolactone treatment also resulted
in a 35% lower frequency of hospitalization for worsening HF.11
However, RALES only enrolled patients with severe HF and signs
of volume overload, and few received b-blocker therapy. In
patients with acute myocardial infarction (MI) complicated by left
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ventricular systolic dysfunction (LVSD) and HF, adding the more
selective AB eplerenone to optimal medical therapy, including
ACE-Is and b-blockers, reduced morbidity and mortality in the
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study (EPHESUS).12 Consequently, current guidelines
recommend ABs in patients with low EF (,35%) and moderate-
to-severe (NYHA class III and IV) HF and in selected patients
after acute MI.13
The efficacy, safety, and tolerability of AB have not been system-
atically evaluated in a large-scale, prospective, randomized study of
patients with LVSD and mild chronic HF.
Although patients with LVSD may be clinically stable
showing few, if any, symptoms for long periods of time, their
clinical course may be complicated by frequent hospital
admissions for worsening HF and a relatively high rate of cardio-
vascular (CV) mortality, the most frequent mode being sudden
cardiac death.14
The aim of the Eplerenone in Mild Patients Hospitalization And
SurvIval Study in Heart Failure (EMPHASIS-HF) is to investigate the
effects of eplerenone vs. placebo added to fully optimized therapy
including an ACE-I (or/and an ARB) and b-blocker in patients with
mild (NYHA functional class II) chronic HF with low EF.
Study design
EMPHASIS-HF is a multicentre, randomized, double-blind,
placebo-controlled study.
The primary objective of this trial is to evaluate the efficacy
and safety of eplerenone plus standard HF therapy vs. placebo
plus standard HF therapy on the cumulative incidence of the
composite endpoint of CV death or HF hospitalization, defined
as the first occurrence of either HF hospitalization or CV
death. The secondary endpoints are the first occurrence of all-
cause mortality or HF hospitalization, all-cause mortality, CV
mortality, all-cause hospitalization, HF hospitalization, all-cause
mortality or all-cause hospitalization, HF mortality or HF hospital-
ization, CV hospitalization, fatal/non-fatal myocardial infarction,
fatal/non-fatal stroke, days alive and out of hospital at one year,
implantation of a cardiac defibrillator, implantation of a resyn-
chronization device, new-onset atrial fibrillation/flutter, new-onset
diabetes mellitus, worsening renal function (if it results in hospi-
talization), and hospitalization for hyperkalaemia. For all events
both the total number of patients experiencing the event as
well as the total number of events will be analysed.
Patient enrolment criteria
Inclusion criteria
Male and female patients aged 55 years or over with the following
criteria are eligible.
(1) A diagnosis of chronic HF and LVSD of either ischaemic or
non-ischaemic aetiology or inoperable valve disease.
(2) Duration of HF must be at least 4 weeks.
(3) Left ventricular ejection fraction ≤30% by echocardiography,
contrast ventriculography, magnetic resonance imaging (MRI)
or nuclear imaging within 6 months of randomization, or
LVEF ≤35% in addition to QRS duration .130 ms. Subjects
with LVEF 31–35% must have QRS duration .130 ms to be
eligible.
(4) New York Heart Association functional class II at
randomization.
(5) Treatment with optimal target or maximal tolerated dose of
ACE-I and/or ARB and b-blocker, unless contra-indicated, as
well as diuretics if clinically indicated.
(6) Serum potassium (K+) ≤5.0 mmol/L within 24 h prior to
randomization.
(7) Estimated glomerular filtration rate (eGFR), using the
Modification of Diet in Renal Disease (MDRD) six-variable
formula, ≥30 mL/min/1.73 m2 within 24 h prior to
randomization.
(8) Randomization must occur within 6 months of a hospitaliz-
ation for CV reasons. In the absence of a history of hospitaliz-
ation for CV reasons, documented plasma B-type natriuretic
peptide (BNP) of at least 250 pg/mL or N terminal proBNP
(NT-proBNP) ≥500 pg/mL for males and ≥750 pg/mL for
females within 15 days prior to randomization. Cardiovascular
hospitalization is defined as hospitalization for HF, acute MI,
unstable angina pectoris, cardiac arrhythmia, stroke, or other
CV reasons such as peripheral arterial disease or hypotension.
Hospitalization for an elective CV procedure does not qualify
for entry into this trial except hospitalization for implantation
of a cardioverter–defibrillator (ICD) or cardiac resynchroniza-
tion therapy (CRT) device.
(9) Subjects previously treated with an AB for more than 7 con-
secutive days must meet the following additional criteria:
(a) No history of clinically significant hyperkalaemia or renal
impairment during previous AB therapy.
(b) Aldosterone blocker therapy discontinued for at least 3
months prior to randomization. Investigators were
instructed not to stop AB in patients just to enter the trial.
Exclusion criteria
Patients are not eligible for enrolment if they present any of the
following criteria:
† an indication for AB treatment according to current HF
guidelines13;
† history of stroke, cardiac surgery, or percutaneous coronary
intervention within 30 days prior to randomization;
† uncontrolled hypertension [systolic blood pressure (SBP)
.180 mmHg and/or a diastolic blood pressure .110 mmHg]
or symptomatic hypotension, or an SBP ,85 mmHg;
† need for adjunctive potassium-sparing diuretic therapy;
† an intra-aortic balloon pump or any other mechanical assist
device;
† scheduled for cardiac transplantation;
† serum potassium .5.0 mmol/L within 24 h prior to
randomization;
† estimated glomerular filtration rate ,30 mL/min/1.73 m2 within
24 h prior to randomization;
† following concomitant therapy with potent cytochrome
P4503A4 inhibitors or inducers;
† blood haemoglobin ,10 g/dL;
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† any other pre-existing and ongoing significant co-morbid
condition.
Dosing regimen
Subjects are started on eplerenone or matching placebo at doses
of 25 mg once daily if eGFR is ≥50 mL/min/1.73 m2, and 25 mg
every other day if eGFR is 30–49 mL/min/1.73 m2. At 4 weeks,
provided that serum potassium is ≤5.0 mmol/L, the dose of
study drug may be increased to 50 mg once daily if eGFR
≥50 mL/min/1.73 m2 and to 25 mg once daily if eGFR is in the
range of 30–49 mL/min/1.73 m2. Study drug dose adjustment or
dose maintenance is guided by safety considerations, mainly by
changes in serum potassium and eGFR which are monitored at
each visit. Investigators are instructed to decrease the dose if pot-
assium is .5.5 mmol/L or withhold the dose if potassium is
.6.0 mmol/L, and to recheck potassium within 72 h and only
restart the dose once potassium drops to ,5.0 mmol/L.
Statistical considerations
Sample size determination
The study was initially designed to enrol a total sample size of 2584
randomized subjects (1292 per treatment group) with at least 80%
power to detect an 18% risk reduction in the primary efficacy
endpoint. This is based on the two-sided log-rank test for
between-treatment comparison in the time to first occurrence
of CV mortality or hospitalization for HF (a composite endpoint)
at a 5% level of significance, assuming an annual event rate of
18% and a 5% annual dropout rate. For a group-sequential trial
with three equal interval efficacy looks (two interim analyses and
the final analysis at trial completion), an expected annual event
rate of 18%, a subject enrolment period of 18 months at most,
an endpoint accrual period of 30 months, an assumed exponential
dropout rate of 5% per year, and a sample size of 2584 (1292 per
treatment group), randomized subjects will be followed until 813
primary events (CV death or HF hospitalization) have occurred.
During the course of the study, a lower than anticipated overall
event rate prompted us to amend the protocol by increasing
sample size to 3100 patients.
Efficacy analysis
The efficacy analysis will be performed on the intent-to-treat
population. The time-to-event distributions will be summarized
by treatment group using Kaplan–Meier estimates of cumulative
incidence. Cox’s proportional hazards regression model will be
used for adjusting the following baseline prognostic factors: age,
eGFR, LVEF, body mass index, haemoglobin, heart rate, SBP, dia-
betes, history of hypertension, prior MI, atrial fibrillation, and left
bundle branch block (LBBB) or QRS .130 ms.
In addition, the primary efficacy endpoint will be analysed on the
following pre-specified subgroups for subjects’ baseline character-
istics: gender, age (,65 and ≥65 years), region (Western Europe/
Australia, Eastern Europe, Asia/Middle East/Africa, and South/
North America), baseline SBP and pulse pressure (less than or
equal to median and greater than median), heart rate (less than
or equal to median and greater than median), eGFR (≤50 and
.50 mL/min/1.73m2), LVEF (≤30 and .30%), LBBB, atrial fibrilla-
tion, diabetes (yes and no), and aetiology of HF (ischaemic and
non-ischaemic HF), prior use of triple neurohumoral blockers
(b-blocker plus ACE-I plus ARB), prior use of b-blocker, prior
use of ACE-I or ARB, history of hypertension, period of prior
CV hospitalization (≤180 days and .180 days), prior CRT, prior
ICD, and QRS .130 ms.
Safety analysis
For all subjects who took at least one dose of study medication
(eplerenone or placebo), the incidence, severity, and relationship
to the study drug of treatment-emergent adverse events will be
summarized by body system and treatment groups. In addition,
the incidence of adverse events causing study drug discontinuation
and serious adverse events will be summarized per treatment
group. Incidence of marked abnormalities in the protocol-specified
laboratory tests will be summarized per treatment group.
Trial oversight
An independent Executive Steering Committee in conjunction with
the sponsor will oversee the conduct of the trial. An independent
Endpoint Adjudication Committee will review the documentation
on clinical endpoint events and determine whether the events
meet the pre-specified criteria. An independent Data Safety Moni-
toring Committee (DSMC) will monitor the safety and efficacy of
the trial and periodically assess whether the trial should continue
as planned (Appendix).
Statistical decision rules and interim analyses
All hypothesis tests will be two-sided. Results will be considered
statistically significant if a P-value ,0.05 is obtained for primary
hypotheses (adjusting for two interim analyses; see the discussion
on interim analyses in what follows). Interim analyses examining
the primary efficacy endpoint will be performed after a total of
approximately 271 and 542 primary endpoint events have
occurred. At the accrual of 542 primary endpoints, the DSMC
may recommend the trial be terminated if either an overwhelming
benefit (two-sided P-value ,0.001 in favour of eplerenone) or an
overwhelming harm (two-sided P-value ,0.01 against eplerenone)
is observed. In addition, the trial will be recommended for termin-
ation in the event of excessive all-cause mortality ascribable to
eplerenone treatment (P-value , 0.01) at any of the interim
looks. Using an adaptation of the Haybittle-Peto stopping criterion,
the P-value for the final primary analysis will be compared with
a ¼ 0.049. No adjustment in a will be made for any looks on par-
ameters/endpoints other than the primary composite endpoint.
Current status
EMPHASIS-HF started enrolling patients in March 2006. As of Feb-
ruary 2010, it had enrolled 2600 patients in 272 centres and 29
countries distributed across all of the major regions worldwide.
Study completion date is estimated at October 2011.
Discussion
The combination of an ACE-I and ab-blocker forms the core basis of
therapy for patients with HF and low LVEF. These drugs have been
proved to decrease morbidity and mortality in patients with HF
across the full spectrum of symptoms (NYHA classes II– IV).15,16
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To date, the efficacy of ABs has only been proved in patients with
severe symptoms (NYHA classes III and IV) and in patients with
low LVEF and clinical evidence of HF (or diabetes) after acute MI.11,12
Patient population
Patients with visibly ‘mild’ symptoms may nevertheless present
severe underlying ventricular dysfunction, and the prognosis
outcome over a 2-to-3-year period after initial diagnosis may be
poor. The event rate in such patients is usually high, though rela-
tively lower than for patients with moderate-to-severe symp-
toms.14 Apart from the now-dated Studies Of Left Ventricular
Dysfunction (SOLVD) prevention study,17 no large-scale studies
have focused exclusively on patients with mild symptoms at the
time of randomization. EMPHASIS-HF will therefore provide
important information on the contemporary natural history of
these patients as well as on the impact of ABs in this setting.
A low event rate is a challenging feature in any outcome trial,
requiring a large population sample size. In EMPHASIS-HF, in
order to spare sample size, we elected to enrich the event rate
by selecting patients aged .55 years. In addition, we restricted
enrolment to patients with a history of recent CV hospitalization
or a high BNP value. Data from the SOLVD17,18 study as well as
from the Candesartan in Heart failure: Assessment of Reduction
in Mortality and morbidity (CHARM) trial19 underline that a
recent history of HF hospitalization is consistently reported to
be associated with a subsequently higher event rate.
Since LVEF is inversely associated with the outcome, we also set
the inclusion LVEF at the relatively low level of ,30%, whereas for
patients with an LVEF ranging 30–35%, we added the additional
risk factor requirement of QRS duration .130 ms. This was
prompted by the fact that QRS prolongation is associated with a
worse outcome in HF patients.20
Aldosterone blockers in patients with
chronic mild heart failure
Current HF guidelines do not recommend the use of ABs in
patients with mild symptoms of HF. European Society of Cardiol-
ogy HF guidelines state that, unless contra-indicated or not toler-
ated, ABs should be considered in patients with low LVEF (,35%)
and moderate-to-severe symptoms, i.e. NYHA classes III and IV, in
the absence of hyperkalaemia and significant renal dysfunction
(Class of recommendation I, Level of Evidence B).13
Few studies have investigated the effect of ABs specifically in
patients with chronic mild-to-moderate systolic HF, and those
that have been published enrolled a small number of patients
and investigated the effect of ABs on surrogate endpoints. None
was adequately powered to investigate mortality and morbidity
outcomes.9,21– 24 All are covered in the systematic review by
Ezekowitz and McAlister.25 One relatively large study, the Anti-
remodelling effect of canrenone in patients with mild chronic
heart failure (AREA IN-CHF), was a randomized, double-blind,
parallel-group comparison of canrenone (up to 50 mg/day), the
active metabolite of spironolactone, against placebo in mild
stable HF.9 The primary endpoint was change in echocardiographic
LV end-diastolic volume over 12 months. Patients had NYHA class
II HF, LVEF ≤45%.21 Left ventricular end-diastolic volume was
similarly reduced in both arms, but LVEF increased more
(P , 0.04) in the canrenone arm (from 40 to 45%) than in the
placebo arm (from 40 to 43%). B-type natriuretic peptide
decreased more in the canrenone arm (37%) than in the placebo
arm (8%; P , 0.0001). The composite endpoint of cardiac death
and hospitalization was significantly lower in the canrenone arm
(8 vs. 15%; P , 0.02). The authors concluded that canrenone on
top of optimal treatment for HF did not have additional effects
on LVEDV but increased LVEF.21 However, the number of clinical
events in this study was relatively small (n ¼ 382) and it was there-
fore unlikely to influence current guidelines and clinical practice.
The Reversal of Cardiac Remodelling with Eplerenone trial
(REMODEL) investigated the effects of eplerenone compared
with placebo on ventricular remodelling assessed by radionuclide
ventriculography in 226 patients presenting with mild-to-moderate
HF and left ventricular dysfunction. Eplerenone did not provide any
additional benefit on LV remodelling in these patients over the
9-month duration of the study.26
Study endpoints
The primary endpoint of EMPHASIS-HF is the cumulative inci-
dence of the composite endpoint of CV death or hospitalization
for HF. This cause-specific endpoint is the most frequently used
primary endpoint in recent and ongoing HF trials. All-cause mor-
tality as a primary endpoint would have been more integrative
and more robust. However, eplerenone is not expected to have
any effect on non-CV deaths, and this endpoint might lead to a
dilution of the expected benefit together with a loss of power,
requiring an even larger sample size.
Several new secondary pre-specified endpoints are included in
the protocol with the aim of generating new hypotheses. Given
the potential effects of ABs on cardiac remodelling and electro-
physiology, the study will investigate the effect of eplerenone on
the implantation of cardiac defibrillators and/or resynchronization
device implantation and of new-onset atrial fibrillation/flutter.
New-onset diabetes mellitus will also be recorded in an attempt
to investigate the possible metabolic effects of eplerenone.
Safety issues
EMPHASIS-HF is also designed to investigate whether the risk–
benefit ratio of adding eplerenone is acceptable in
mild-to-moderate HF. Spironolactone, even at modest doses, has
undesirable side effects, particularly gynaecomastia, which is not
observed with the more selective MR-blocker eplerenone. Both
have hyperkalaemia as an obligate adverse effect, reflecting the
renal tubular effects of MR blockade. Previous trials with eplere-
none show that, with careful titration, there appears to be only a
very modest increase of ,0.3 mmol/L in plasma potassium, even
at high doses (200 mg).27 Similar to the RALES and EPHESUS
trials, the carefully set inclusion/exclusion criteria for EMPHASIS-
HF are intended to minimize the risk of hyperkalaemia and
worsening renal function. Furthermore, the investigators are
instructed to use a pre-defined dose titration algorithm based on
serum potassium and creatinine levels measured at each visit.
However, there is still a real risk of hyperkalaemia in elderly
patients and/or diabetic patients with a low eGFR, particularly at
higher doses and/or when potassium supplementation is used.28
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Specific serious safety concerns over hyperkalaemia and renal
function will be closely monitored. Hospitalization for worsening
renal function and/or hyperkalaemia will be prospectively docu-
mented and adjudicated.
In patients with mild HF receiving optimal therapy including
b-blockers, the balance between risk and benefit might not be as
favourable as in the RALES and EPHESUS trials due to the patients’
lower absolute risk of a CV event and likely lower absolute
reduction of CV risk with eplerenone. However, a subgroup analy-
sis of the Candesartan in Heart failure: Assessment of Reduction in
Mortality and morbidity (CHARM)-Added trial has shown that in
HF patients already taking spironolactone as well as an ACE-I
and b-blocker, the addition of the ARB candesartan appeared to
provide added benefit at acceptable risk.29
Conclusion
Heart failure with low LVEF but mild symptoms is a frequent con-
dition that is still associated with poor outcome. Few trials have
exclusively enrolled patients with this profile. If positive, the
results of EMPHASIS-HF would extend the use of AB in HF with
low LVEF. They would provide more safety data and expand the
range of patients with low LVEF eligible for an AB, as well as
provide additional safety information that should be of value in
guiding clinical practice.
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P.H.J.M. Dunselman, M.C.G. Daniëls, D.J.A. Lok, A. Dirkali, J.A.
Kragten, H.J.M. Thijssen, A.A. Voors, A.H.E.M. Maas, H. Heuer,
U. Ahremark, M. Fu, B. Andersson, I.I. Sakharchuk, G.V. Dzyak, H.R.
Michels, P.M.M. Orbe, M.V. Perepelytsya, M. Komajda, P. Attali,
A. Bonneau, B.D. Hautefeuille, F. Funck, P. Gibelin, L. Hittinger,
M. Carrageta, S. Berglund, U. Axelsson, J.L. Serra, U. Dahlstrom,
W. Van Mieghem, B. Marchandise, A.C. Van Dorpe, F.P.P. Charlier,
P. Dendale, J. Vanhaecke, G.F. Gensini, E. Maupas, G.Q. Villani,
G. Roul, J.-N. Trochu, K. Boman, P. Vasko, G. De Keulenaer,
D. Rucka, V. Vizir, T.O. Pertseva, O.V. Kuryata, G.S. Popik, J.M.
Thierer, M. Lindgren, D. Nul, G. Boffa, N.P. Shilkina, Y.B. Karpov,
A. Stenberg, A. Johansson, H. Prantare, P. Poliacik, F. Marenne,
N. Bazargani, D.E. Allaf, J.-L. Boreux, V. Ambrovicova,
F. Petersen-Aranguren, G. Stehn, J. Takacs, K. Swedberg, J.J. McMurray,
O.M. Girina, G.I. Obraztsova, E.V. Shlyakhto, A. Skvortsov, R.G.
Velasco-Sanchez, Y.P. Nikitin, W.A. Almahmeed, R. Leischik,
A. Foerster, N. Franz, G.B. Bon, G.B. Ambrosio, Z. Gaciong,
A. Karavidas, C. Czibok, P. Kycina, A. Philias, P. Nash, R. Ramani, I.S.
Anand, D. Wencker, F.A. McGrew, D.A. Henderson, C.M. Schmalfuss,
J.A. Lash, D.S. Primack, D. Moraes, W.R. Herzog, E.J. Kosinski, A.H.
Wiseman, C.S. Breburda, R.J. Dahiya, C.B. Treasure, U. Thadani,
J.-W. Ha, S.C. Murali, M.R. Berk, J.-H. Shin, M. Nallasivan, A.R. Flores,
F.L. Lally, D. Rawitscher, L. Stoletniy, K. Gindin, V.A. Kostenko, B.D.
Bertolet, R. Sangrigoli, E. Philbin, A. Cruz-Diaz, R.S. McKelvie, M.N.
Walsh, J.M. Arnold, S.M. Kouz, S. Lepage, G. Proulx, T. Huynh,
E. O’Meara, R.C. Capodilupo, C.D. Vogel, J.L. Anderson, S.-C. Chae,
E. Bayram-Llamas, M. Ogorek, M. Ujda, S.M. Mohiuddin, W.S.
Colucci, R.J. Katz, S.H. Dunlap, E. Winkel, R.M. Vicari, R.D. Blonder,
C. Sauve, T. Olive, M.P. Galinier, Y. Jobic,
References
1. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hyperten-
sion 2009;53:286–290.
2. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA,
McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory pheno-
type in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802–H1810.
3. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A,
Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in
Rationale and design of the EMPHASIS-HF 621
rat myocardial infarction: effect of angiotensin II receptor blockade and role in
cardiac fibrosis. Circulation 1999;99:2694–2701.
4. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling.
The role of aldosterone. J Mol Cell Cardiol 2002;34:1577–1584.
5. Struthers AD. The clinical implications of aldosterone escape in congestive heart
failure. Eur J Heart Fail 2004;6:539–545.
6. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting
enzyme inhibitor therapy. Am J Hypertens 2003;16:781–788.
7. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, Nicholls MG,
Sanderson JE. Effect of beta blockade (carvedilol or metoprolol) on activation
of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic
heart failure. Am J Cardiol 2003;92:406–410.
8. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT,
White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of can-
desartan, enalapril, and their combination in congestive heart failure: randomized
evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.
The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056–1064.
9. Boccanelli A, Cacciatore G, Mureddu GF, de Simone G, Clemenza F, De Maria R,
Di Lenarda A, Gavazzi A, Latini R, Masson S, Porcu M, Vanasia M, Gonzini L,
Maggioni AP. Baseline characteristics of patients recruited in the AREA IN-CHF
study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canre-
none in Mild Chronic Heart Failure). J Cardiovasc Med (Hagerstown) 2007;8:
683–691.
10. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R. Sustained reduction
of aldosterone in response to the angiotensin receptor blocker valsartan in
patients with chronic heart failure: results from the Valsartan Heart Failure
Trial. Circulation 2003;108:1306–1309.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
The effect of spironolactone on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J
Med 1999;341:709–717.
12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S,
Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with
left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:
1309–1321.
13. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the diagnosis and treatment of acute and chronic heart failure 2008
of the European Society of Cardiology. Developed in collaboration with the
Heart Failure Association of the ESC (HFA) and endorsed by the European
Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–989.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Random-
ised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:
2001–2007.
15. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-
converting enzyme inhibitor versus the combination of angiotensin-converting
enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular
dysfunction: a systematic review and meta-analysis of randomized controlled
trials. J Card Fail 2008;14:181–188.
16. Williams RE. The effect of neurohormonal antagonists in reducing heart failure
hospitalizations. Curr Med Res Opin 2006;22:139–150.
17. Effect of enalapril on mortality and the development of heart failure in asympto-
matic patients with reduced left ventricular ejection fractions The SOLVD Inves-
tigators. N Engl J Med 1992;327:685–691.
18. Gustafsson F, Schou M, Videbaek L, Dridi N, Ryde H, Handberg J, Hildebrandt PR.
Incidence and predictors of hospitalization or death in patients managed in multi-
disciplinary heart failure clinics. Eur J Heart Fail 2009;11:413–419.
19. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S,
Swedberg K, Young JB, Michelson EL, Pfeffer MA. Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM) Investigators.
Influence of nonfatal hospitalization for heart failure on subsequent mortality in
patients with chronic heart failure. Circulation 2007;116:1482–1487.
20. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr,
Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C,
Gheorghiade M. Clinical implications of QRS duration in patients hospitalized
with worsening heart failure and reduced left ventricular ejection fraction.
JAMA 2008;299:2656–2666.
21. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A,
Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G. Anti-
remodelling effect of canrenone in patients with mild chronic heart failure (AREA
IN-CHF study): final results. Eur J Heart Fail 2009;11:68–76.
22. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y,
Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor
antagonism induces reverse remodeling when added to angiotensin receptor
blockade in chronic heart failure. J Am Coll Cardiol 2007;50:591–596.
23. Berry C, Murphy NF, De Vito G, Galloway S, Seed A, Fisher C, Sattar N,
Vallance P, Hillis WS, McMurray J. Effects of aldosterone receptor blockade in
patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail
2007;9:429–434.
24. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial
function, vascular angiotensin converting enzyme activity, and other prognostic
markers in patients with mild heart failure already taking optimal treatment.
Heart 2004;90:765–770.
25. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunc-
tion: a systematic review of randomized clinical trials. Eur Heart J 2009;30:
469–477.
26. Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA,
Konstam MA. Randomized, double-blind, multicenter, placebo-controlled study
evaluating the effect of aldosterone antagonism with eplerenone on ventricular
remodeling in patients with mild-to-moderate heart failure and left ventricular
systolic dysfunction. Cir Heart Fail. Published online ahead of print 18 March 2010.
27. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte
effects of eplerenone. J Clin Endocrinol Metab 2004;89:2736–2740.
28. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A,
Redelmeier DA. Rates of hyperkalemia after publication of the Randomized
Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.
29. Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S,
Michelson EL, Swedberg K, Pfeffer MA. Efficacy and tolerability of adding an angio-
tensin receptor blocker in patients with heart failure already receiving an
angiotensin-converting inhibitor plus aldosterone antagonist, with or without a
beta blocker. Findings from the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail
2008;10:157–163.
F. Zannad et al.622
